Ranking Alexa Global: # 11,907,903
Server:Apache...
X-Powered-By:PleskLin
The main IP address: 82.165.151.221,Your server United States,Chesterbrook ISP:1&1 Internet AG TLD:uk CountryCode:US
The description :home about research & development news & events contact us home about research & development news & events contact us reviral drug discovery for respiratory syncytial virus (rsv) revir...
This report updates in 15-Jun-2018
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host reviral.co.uk. Currently, hosted in United States and its service provider is 1&1 Internet AG .
Latitude: | 40.075660705566 |
Longitude: | -75.459083557129 |
Country: | United States (US) |
City: | Chesterbrook |
Region: | Pennsylvania |
ISP: | 1&1 Internet AG |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.
X-Powered-By: | PleskLin |
Transfer-Encoding: | chunked |
Set-Cookie: | CMSSESSID5409ecdd099c=841r4dti5el1bfdj5n0tp83jl1; path=/ |
Expires: | Thu, 19 Nov 1981 08:52:00 GMT |
Server: | Apache |
Connection: | close |
Pragma: | no-cache |
Cache-Control: | no-store, no-cache, must-revalidate, post-check=0, pre-check=0 |
Date: | Thu, 14 Jun 2018 18:35:15 GMT |
Content-Type: | text/html; charset=utf-8 |
soa: | ns.123-reg.co.uk. hostmaster.reviral.co.uk. 2012031012 86400 3600 1209600 14400 |
txt: | "4vqbn0tbaq09phj9rq5jl47uuo" " v=spf1 include:spf.protection.outlook.com -all" "MS=ms74085353" |
ns: | ns.123-reg.co.uk. ns2.123-reg.co.uk. |
ipv4: | IP:82.165.151.221 ASN:8560 OWNER:ONEANDONE-AS Brauerstrasse 48, DE Country:DE |
mx: | MX preference = 1, mail exchanger = reviral-co-uk.mail.protection.outlook.com. |
home about research & development news & events contact us home about research & development news & events contact us reviral drug discovery for respiratory syncytial virus (rsv) reviral is a uk-based biotechnology company with a portfolio of drugs to treat respiratory syncytial virus (rsv) infection. rsv currently represents a major unmet medical need in children, the elderly and the immunocompromised. our most advanced programme, rv521, is a highly potent, orally-administered inhibitor of rsv fusion protein, and has demonstrated top-line safety and pharmacokinetic data in phase 1 single and multiple ascending dose (sad and mad) trials. rv521 has successfully completed a phase 2a proof-of-concept study in adult volunteers. rv521 will start clinical trials in patients in 2018. rv521 best-in-class drug to treat rsv infections rv521 is an orally available antiviral with excellent drug-like characteristics binds to the rsv fusion protein, blocking viral entry and preventing cell-to-cell spread the compound demonstrates potent activity against multiple clinical strains of rsv rsv medical need rsv is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly currently, there are no effective treatments or vaccines available against rsv there is a clear unmet need for a safe and effective treatment with a simple route of administration meet the team... dr ken powell chairman dr eddy littler chief executive officer dr stuart cockerill chief scientific officer, founder dr rachel harland chief operating officer dr neil mathews project director, founder max herrmann chief financial officer dr elaine thomas head of virology latest news presentation at the american thoracic society reviral is pleased to announce that professor john devincenzo from the department of pediatrics, university of tennessee, memphis, usa will be presenting at the american... read more... reviral to present at american chemical society reviral's chief scientific officer, stuart cockerill, will be presenting at the american chemical society in new orleans. the afternoon session entitled "medi: first time... read more... positive results achieved in reviral’s phase iia rsv challenge study reviral’s rv521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms london, uk, 5th february... read more... contact us... name email message reviral ltd registered office stevenage bioscience catalyst gunnels wood road stevenage hertfordshire sg1 2fx england [email protected] find us on twitter © reviral ltd 2018
https://www.reviral.co.uk/news-events.html
https://www.reviral.co.uk//home
https://www.reviral.co.uk/
https://www.reviral.co.uk/contact-us.html
https://www.reviral.co.uk/news/32/48/reviral-to-present-at-american-chemical-society.html
https://www.reviral.co.uk//mailto:[email protected]
https://www.reviral.co.uk/research-development.html
https://www.reviral.co.uk/news/33/48/presentation-at-the-american-thoracic-society.html
https://www.reviral.co.uk/news/31/48/positive-results-achieved-in-revirals-phase-iia-rsv-challenge-study.html
https://www.reviral.co.uk/about.html
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Error for "reviral.co.uk".
the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 228 seconds
WHOIS lookup made at 02:43:40 14-Jul-2017
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REFERRER http://www.nominet.org.uk
REGISTRAR Nominet UK
SERVERS
SERVER co.uk.whois-servers.net
ARGS reviral.co.uk
PORT 43
TYPE domain
DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REGISTERED no
DOMAIN
NAME reviral.co.uk
NSERVER
NS2.123-REG.CO.UK 62.138.132.21
NS.123-REG.CO.UK 212.67.202.2
The following list shows you to spelling mistakes possible of the internet users for the website searched .